Two new dry eye disease (DED) treatments have recently been approved by the FDA.

In May, the FDA approved MIEBO (perfluorohexyloctane ophthalmic solution; formerly known as NOV03) from Bausch + Lomb Corporation and Novaliq GmbH. Approved for the treatment of both signs and symptoms of DED, MIEBO is designed to reduce tear evaporation at the ocular surface.

In June, the FDA approved VEVYE (cyclosporine ophthalmic solution) 0.1%, from Novaliq GmbH. VEVYE is described as a cyclosporine solution indicated for DED treatment with efficacy demonstrated after 4 weeks of treatment. The solution does not contain water or anti-microbial preservatives, oils or surfactants. As a water-free product, there is no associated pH and no osmolarity. OM